Novartis (NVS) News
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
143.75+0.64 (+0.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NVS news summary
We found 32 recent headlines mentioning Novartis (NVS): 4 in the past week and 20 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, NVS is up 0.45% at $143.75. The most recent story, "Cancer Stocks to Consider as Oncology Innovation Accelerates", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Novartis headlines
- Cancer Stocks to Consider as Oncology Innovation AcceleratesOncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.NasdaqABT, PFE, MMSI, AZN
- NVS Wins FDA Nod for Label Expansion of Immunology Drug RhapsidoNovartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.NasdaqNVS, PFE
- Novartis Wins FDA Approval For First Symptomatic Dermographism Treatment(RTTNews) - Novartis (NVS) announced Wednesday that the U.S. FDA has approved Rhapsido for adults with symptomatic dermographism whose symptoms remain inadequately controlled by H1 antihistamines.…NasdaqNVS, BRK.A
- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.NasdaqNVS, IONS, ACIU, PGEN
- Novartis Signs Deal With Abogen For MRNA Therapies(RTTNews) - Swiss pharmaceutical company Novartis AG (NVS) announced it has entered into a licensing and option agreement with China-based Abogen Biosciences to develop mRNA-encoded therapies,…Nasdaq
- Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionAGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.NasdaqAGIO, NVS, BMY, NVO
- Novartis inks up to $7.8B deal with Abogen for RNA-encoded therapeuticsSeeking Alpha
- Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.NasdaqVRTX, NVS, VERA
- Ionis Delivers Positive Late-Stage Results for Two Partnered DrugsIONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.NasdaqIONS, AZN, NVS
- BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln(RTTNews) - BoomRay Pharmaceuticals Co., Ltd., a clinical-stage biotechnology company, announced an exclusive global license agreement with Novartis Pharma AG (NVS) for an undisclosed preclinical…Nasdaq
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.NasdaqNVS, RGEN, ANIK, IONS
- Novartis' Pipeline In Focus After A Series Of Clinical Setbacks(RTTNews) - Novartis has come under increasing pressure after a series of clinical and pipeline setbacks in the second half of 2026, culminating in calls from a major shareholder for changes to the…Nasdaq
- Novartis Gains Positive CHMP Opinion For Cosentyx In Polymyalgia Rheumatica; EC Decision By Nov '26(RTTNews) - Novartis AG (NVS), a pharmaceutical company, on Friday reported receiving a positive opinion from the Centre for Human use of Medicinal Products (CHMP) for Cosentyx in the treatment of…Nasdaq
- Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?Key PointsCRISPR Therapeutics will likely be a much larger company in 10 years.NasdaqCRSP, NVS, VRTX
- Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint(RTTNews) - Novartis (NVS) announced on August 25, 2026, that its ASTRALS Phase 2 clinical trial evaluating VHB937 for amyotrophic lateral sclerosis did not meet its primary or secondary endpoints,…NasdaqALEC, NVS
- Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022Key PointsAmgen has proven that it can manage market downturns fairly well.NasdaqAMGN, NVS
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and JanuxProstate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.NasdaqNVS, PFE, JANX, CADL
- 4 Prostate Cancer Drug Stocks to Watch During Awareness MonthPfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.NasdaqNVS, PFE, JANX, CADL
- INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.NasdaqINCY, GSK, NVS
- Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade)Seeking AlphaAMGN, NVS
- Tuesday's ETF Movers: COPX, PPHIn trading on Tuesday, the Global X Copper Miners ETF is outperforming other ETFs, up about 5.5% on the day. Components of that ETF showing particular strength include shares of Ivanhoe Electric, up…NasdaqIE, ERO, NVS, HLN
- Novartis: 2 Significant Pipeline Setbacks Can Be AbsorbedSeeking Alpha
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB
- Novartis: Today's Positive Remibrutinib Data Key To Unlocking Growth PlansSeeking Alpha
- Noteworthy ETF Outflows: AVSD, HSBC, NVS, MUFGLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis Responsible International Equity ETF (Symbol: AVSD) where we…NasdaqAVSD, HSBC, NVS, MUFG
- Novartis: The Buy Thesis Is Back (Rating Upgrade)Seeking Alpha
- Novartis AG (NVS) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Pre-Market Earnings Report for July 21, 2026 : SCHW, DHR, MRSH, MMM, NOC, GM, MSCI, DHI, HAL, NVS, KEY, SYFThe following companies are expected to report earnings prior to market open on 07/21/2026. Visit our Earnings Calendar for a full list of expected earnings releases.The Charles Schwab Corporation…NasdaqSCHW, DHR, MRSH, MMM
- VYMI vs. VIGI: Which International Dividend ETF Is Better?Key PointsRecent research from Vanguard suggests that international stocks in developed markets could outperform U.S. stocks in the next 10 years.NasdaqVYMI, BHP, NVS, HSBC
- Novartis' Pipeline Building Continues, Pelacarsen Readout Coming SoonSeeking Alpha
- New Research Says: The Biggest Gains of AI Won't Go to AI Stocks. These 2 ETFs Could Be Better Buys.Key PointsVanguard research from June projects that U.S. value stocks and international developed-market stocks might outperform in the future era of AI-driven productivity.NasdaqVBR, NVS, TD, RY
- Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 CatalystsSeeking Alpha